120 related articles for article (PubMed ID: 36316091)
1. Differences in Phosphate and Parathyroid Hormone Concentrations over the Day among Patients on Hemodialysis.
Ginsberg C; Miller LM; Ofsthun N; Dalrymple LS; Ix JH
J Am Soc Nephrol; 2022 Nov; 33(11):2087-2093. PubMed ID: 36316091
[TBL] [Abstract][Full Text] [Related]
2. Circadian variation of mineral and bone parameters in end-stage renal disease.
Trivedi H; Szabo A; Zhao S; Cantor T; Raff H
J Nephrol; 2015 Jun; 28(3):351-9. PubMed ID: 25138650
[TBL] [Abstract][Full Text] [Related]
3. Calcium, phosphate, and PTH levels in the hemodialysis population: a multicenter study.
Gallieni M; Cucciniello E; D'Amaro E; Fatuzzo P; Gaggiotti A; Maringhini S; Rotolo U; Brancaccio D;
J Nephrol; 2002; 15(2):165-70. PubMed ID: 12018633
[TBL] [Abstract][Full Text] [Related]
4. Effectiveness of phosphate binders in adult patients with end stage renal disease receiving hemodialysis: a systematic review.
Gasu V; Ashong M; Seferi A; Fitzpatrick A
JBI Database System Rev Implement Rep; 2019 Jan; 17(1):49-73. PubMed ID: 30204711
[TBL] [Abstract][Full Text] [Related]
5. Association between Biomarkers of Mineral and Bone Metabolism and Removal of Calcium and Phosphate in Hemodialysis.
Debowska M; Dai L; Wojcik-Zaluska A; Poleszczuk J; Zaluska W; Lindholm B; Waniewski J
Blood Purif; 2020; 49(1-2):71-78. PubMed ID: 31726453
[TBL] [Abstract][Full Text] [Related]
6. 1alpha(OH)D3 One-alpha-hydroxy-cholecalciferol--an active vitamin D analog. Clinical studies on prophylaxis and treatment of secondary hyperparathyroidism in uremic patients on chronic dialysis.
Brandi L
Dan Med Bull; 2008 Nov; 55(4):186-210. PubMed ID: 19232159
[TBL] [Abstract][Full Text] [Related]
7. Comparative Effectiveness of Dialysis Modality on Laboratory Parameters of Mineral Metabolism.
Soohoo M; Obi Y; Rivara MB; Adams SV; Lau WL; Rhee CM; Kovesdy CP; Kalantar-Zadeh K; Arah OA; Mehrotra R; Streja E
Am J Nephrol; 2022; 53(2-3):157-168. PubMed ID: 35226895
[TBL] [Abstract][Full Text] [Related]
8. Effect of serum phosphate on parathyroid hormone secretion during hemodialysis.
de Francisco AL; Cobo MA; Setien MA; Rodrigo E; Fresnedo GF; Unzueta MT; Amado JA; Ruiz JC; Arias M; Rodriguez M
Kidney Int; 1998 Dec; 54(6):2140-5. PubMed ID: 9853280
[TBL] [Abstract][Full Text] [Related]
9. Co-trending of parathyroid hormone and phosphate in patients receiving hemodialysis.
Block G; Do TP; Collins AJ; Cooper KC; Bradbury BD
Clin Nephrol; 2016 Mar; 85(3):142-51. PubMed ID: 26784912
[TBL] [Abstract][Full Text] [Related]
10. Circadian rhythm of serum phosphate, calcium and parathyroid hormone levels in hemodialysis patients.
Micozkadioglu H; Ozelsancak R; Yildiz I; Erken E; Zumrutdal A; Torun D; Haberal M
Clin Lab; 2013; 59(1-2):79-84. PubMed ID: 23505910
[TBL] [Abstract][Full Text] [Related]
11. Effect Modifying Role of Serum Calcium on Mortality-Predictability of PTH and Alkaline Phosphatase in Hemodialysis Patients: An Investigation Using Data from the Taiwan Renal Registry Data System from 2005 to 2012.
Lin YC; Lin YC; Hsu CY; Kao CC; Chang FC; Chen TW; Chen HH; Hsu CC; Wu MS;
PLoS One; 2015; 10(6):e0129737. PubMed ID: 26107510
[TBL] [Abstract][Full Text] [Related]
12. Mineral Metabolism Markers Are Associated with Myocardial Infarction and Hemorrhagic Stroke but Not Ischemic Stroke in Hemodialysis Patients: A Longitudinal Study.
Tagawa M; Hamano T; Nishi H; Tsuchida K; Hanafusa N; Fukatsu A; Iseki K; Tsubakihara Y
PLoS One; 2014; 9(12):e114678. PubMed ID: 25494334
[TBL] [Abstract][Full Text] [Related]
13. [Changes in mineral metabolism in stage 3, 4, and 5 chronic kidney disease (not on dialysis)].
Lorenzo Sellares V; Torregrosa V
Nefrologia; 2008; 28 Suppl 3():67-78. PubMed ID: 19018742
[TBL] [Abstract][Full Text] [Related]
14. Conversion from Intravenous Vitamin D Analogs to Oral Calcitriol in Patients Receiving Maintenance Hemodialysis.
Thadhani RI; Rosen S; Ofsthun NJ; Usvyat LA; Dalrymple LS; Maddux FW; Hymes JL
Clin J Am Soc Nephrol; 2020 Mar; 15(3):384-391. PubMed ID: 32111702
[TBL] [Abstract][Full Text] [Related]
15. Etelcalcetide Utilization, Dosing Titration, and Chronic Kidney Disease-Mineral and Bone Disease (CKD-MBD) Marker Responses in US Hemodialysis Patients.
Karaboyas A; Muenz D; Fuller DS; Desai P; Lin TC; Robinson BM; Rossetti S; Pisoni RL
Am J Kidney Dis; 2022 Mar; 79(3):362-373. PubMed ID: 34273436
[TBL] [Abstract][Full Text] [Related]
16. Long-term dialysis with low-calcium solution (1.0 mmol/L) in CAPD: effects on bone mineral metabolism. Collaborators of the Multicenter Study Group.
Weinreich T; Ritz E; Passlick-Deetjen J
Perit Dial Int; 1996; 16(3):260-8. PubMed ID: 8761540
[TBL] [Abstract][Full Text] [Related]
17. Effect of CAPD and hemodialysis on parathyroid function.
Malberti F; Corradi B; Imbasciati E
Adv Perit Dial; 1996; 12():239-44. PubMed ID: 8865912
[TBL] [Abstract][Full Text] [Related]
18. Parathyroid Hormone Serum Levels and Mortality among Hemodialysis Patients in the Gulf Cooperation Council Countries: Results from the DOPPS (2012-2018).
Al Salmi I; Bieber B; Al Rukhaimi M; AlSahow A; Shaheen F; Al-Ghamdi SMG; Al Wakeel J; Al Ali F; Al-Aradi A; Hejaili FA; Maimani YA; Fouly E; Robinson BM; Pisoni RL
Kidney360; 2020 Oct; 1(10):1083-1090. PubMed ID: 35368779
[TBL] [Abstract][Full Text] [Related]
19. Hysteresis of the parathyroid hormone response to hypocalcemia in hemodialysis patients with low turnover aluminum bone disease.
Felsenfeld AJ; Ross D; Rodriguez M
J Am Soc Nephrol; 1991 Dec; 2(6):1136-43. PubMed ID: 1777594
[TBL] [Abstract][Full Text] [Related]
20. Calcium-phosphate and parathyroid intradialytic profiles: A potential aid for tailoring the dialysate calcium content of patients on different hemodialysis schedules.
Ferraresi M; Pia A; Guzzo G; Vigotti FN; Mongilardi E; Nazha M; Aroasio E; Gonella C; Avagnina P; Piccoli GB
Hemodial Int; 2015 Oct; 19(4):572-82. PubMed ID: 25819092
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
